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Abstract
Purpose To compare patients’ evaluation of the treatment decision-making process in localized prostate cancer between counsel-
ing that included an online decision aid (DA) and standard counseling.
Methods Eighteen Dutch hospitals were randomized to DA counseling (n = 235) or the control group with standard counseling
(n = 101) in a pragmatic, cluster randomized controlled trial. The DA was provided to patients at, or soon after diagnosis.
Decisional conflict, involvement, knowledge, and satisfaction with information were assessed with a questionnaire after treat-
ment decision-making. Anxiety and depression served as covariates.
Results The levels of decision involvement and conflict were comparable between patients in both groups. Patients with
a DA felt more knowledgeable but scored equally well on a knowledge test as patients without a DA. Small significant
negative effects were found on satisfaction with information and preparation for decision-making. A preference for print
over online and depression and anxiety symptoms was negatively associated with satisfaction and conflict scores in the
DA group.
Discussion The DA aimed to support shared decision-making, while outcomes for a majority of DA users were comparable to
patients who received standard counseling. Patients, who are less comfortable with the online DA format or experience anxiety or
depression symptoms, could require more guidance toward shared decision-making. To evaluate long-termDA effects, follow-up
evaluation on treatment satisfaction and decisional regret will be done.
Keywords Shared decision-making . Decision aids . Prostate cancer . Oncology . Information provision . Patient-reported
outcomes
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Background
In a clinical area where multiple equal effective treatments are
available for the same medical condition, the preference-
sensitive treatment selection that is then required can be chal-
lenging for patients as well as physicians [1–3]. Treatment
selection for localized prostate cancer (Pca), the most com-
monly detected cancer in men in the Western world, is such
an area [4]. When diagnosed at a localized stage, Pca can be
managed with equal successful curative treatments (surgery or
radiotherapy), or by following an active surveillance (AS) pro-
tocol without harming survival perspectives [5–8]. Although
oncologically equivalent, treatments differ in their impact on
quality of life, risk of side effects, and perceived burden; there-
fore, Pca treatment guidelines do not indicate a single superior
treatment option, but recommend shared decision-making
(SDM) to come to the best patient-treatment fit [5, 6, 9–11].
Moreover, many Pca patients have a poor understanding of
differences in treatment risks prior to choosing treatment, are
dissatisfied with information received, and experience regret
after treatment [12–14].With SDM andmore decision support,
these problems can be resolved.
SDM requires patients to share preferences, uncertainties,
and the desired level of participation in the decision process. A
physician should be aware of the patient’s preferred level of
involvement and take this into account to adequately provide
all available information about eligible options, including
risks, benefits, and scientific uncertainties [15, 16]. However,
patient preferences for involvement are oftenmisinterpreted by
care providers and many patients are dissatisfied with the in-
formation they received [17–20].
To facilitate and improve the process of SDM, patient de-
cision aids (DAs) were developed to help patients to increase
choice awareness, provide high quality information, structure
the decision process, and to help clarify preferences and
values [21–23]. Simple DAs are plain paper versions, while
more elaborate DAs are built as interactive websites that in-
clude explicit values clarification methods [24, 25]. DA ef-
fects are typically studied by comparing patient-reported out-
comes following decision-making between a DA group and a
usual care group. In a review of DAs across all medical
screening and treatment decisions, it has been shown that
DAs contribute to improved patient involvement in the treat-
ment decision, less decisional conflict, and more conservative
treatment choices [26].
In the specific area of Pca treatment decision-making, DA
results are less conclusive. Positive effects are seen for im-
proved patient education (knowledge, information satisfac-
tion), but mixed effects are found for other decision process
measures, such as decisional conflict [27]. Often the studied
Pca DAs did not fully comply with the International Patient
Decision Aid Standards (IPDAS), mostly because of missing
DA development information or unbalanced presentation of
treatment benefits and risk. Furthermore, they lacked a user-
centered design or were not specifically aimed at facilitating
SDM in the patient-doctor encounter [23, 27–29].
In the absence of a Dutch Pca treatment DA that included a
values clarification method, a novel web-based DAwas devel-
oped with a specific user-centered focus on facilitating SDM
[30]. A cluster randomized controlled trial (RCT) that com-
pared DA counseling to a control armwith standard counseling
was set up. The primary finding, that the DA helped patients
align treatment choices to their personal preferences, was pub-
lished previously [31]. The current study investigated patient-
reported outcomes related to the decision-making process, di-
rectly following treatment decision-making. We hypothesized
that with the DA decisional conflict (primary outcome) would
be lower and patient involvement, Pca knowledge and infor-
mation satisfaction (secondary outcomes) would be better,
compared to the control group [18]. Moreover, we were inter-
ested in individual differences (DA format preference, anxiety,
and depression symptoms) among DA users to explain poten-
tial differences in outcomes within the trial’s DA arm.
Methods
Participants and recruitment
All patients from participating hospitals, who were newly di-
agnosed with localized Pca (PSA < 20, Gleason < 8) between
August 1, 2014 and July 1, 2016, had at least two treatment
options and no mental or cognitive impairments, were suitable
for enrollment in this trial. Patients were recruited at diagnosis,
by their urologist or by an (oncology) nurse, immediately fol-
lowing diagnosis, and were given a study package containing
an information letter, informed consent form, leaflet, and a pre-
stamped envelope. To agree with participation, the informed
consent form had to be returned using the pre-stamped enve-
lope. On the informed consent form, patients indicated the date
of their next consultation, which usually was 2 or 3 weeks
following diagnosis and the moment to discuss treatment
choice. A questionnaire was sent within 1 week after this indi-
cated date by email (paper version on request) [18].
Design
Eighteen Dutch hospitals were randomized to the intervention
or control arm. All hospitals were general hospitals, except for
one academic hospital in the control arm. Patients in the con-
trol arm received information and counseling as usual, pa-
tients from hospitals in the intervention arm received access
to the online DA in addition to usual information and counsel-
ing. Randomization at hospital level was chosen to avoid con-
tamination of usual counseling with components of the DA.
Patients were informed that the topic of the study was to
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evaluate information provision and treatment decision-
making in Pca care, and were unaware of assignment to trial
arm as the DAwas not mentioned as subject of this study. The
regional Medical Ethics Review Board waived the need for
formal ethical approval (reference: NW2014-03), and the
study protocol was approved by every individual hospital.
The study was pre-registered in the Dutch Trial Register
(NTR4554).
Intervention
To invite patients to use the DA, patients in the intervention
arm received an access card from their health care provider
with the DA-web address and a unique username and pass-
word. The card also stated the patient’s relevant clinical char-
acteristics, that is, eligible treatment options (AS, surgery,
brachytherapy, or external radiation), PSA, and Gleason score.
Based on the indicated treatment options, the DA allowed
patients to skip information about non-eligible treatments.
After accessing the DA and entering the clinical data from
the card, patients first could read general information about
Pca, before detailed information about AS and treatments was
provided. Provided treatment information within the DAwas
similar for each treatment and consisted of information about
procedures, risks, and pros and cons. Information was based
on (inter)national guidelines and recent scientific literature.
Values clarification methods (VCMs) were included to help
patients clarify their personal preference for AS or any of the
treatments. VCMs were designed as statements that required a
trade-off between two treatment modalities (e.g. BIf treatment
might be unnecessary, I prefer to wait,^ as trade-off between
AS and treatment). The DA ended with a summary page that
displayed how extensive the DA was used (e.g. BYou have
read x out of x topics^), the patient’s responses to the VCMs
and indicated treatment preference. A printed summary could
be taken to the subsequent consultation where the treatment
decision was discussed with the urologist. The goal of the
summary page is to enable a SDM conversation as it presents
the patient’s preferences on the various VCMs and for treat-
ment. A more detailed description of the development and
content of this novel Dutch web-based DA is available in a
separate publication, which also provides evidence for IPDAS
compliance of the current DA [28, 30].
Procedures
In addition to usual information, patients in the intervention
arm were granted access to the online DA. The pragmatic
aspect of the current trial allowed hospitals to follow their
existing procedures and routines for further counseling. For
some hospitals, this meant that all newly diagnosed patients
saw a radiation oncologist (when eligible for radiotherapy)
and an oncology nurse, while at other hospitals this only
happened by patient request. Most patients took 2 or 3 weeks
to consider their treatment choice before a follow-up consul-
tation was scheduled. Patients in the intervention arm received
explanation that the DA should be used during this period, and
that the summary provided by the DA, could be taken to the
next consultation, although this was not mandatory. In the
week following the treatment decision, patients in both arms
were invited to fill out the questionnaire online or a paper
questionnaire was sent on request. Automatic reminders were
sent after 2 and 4 weeks if the questionnaire had not yet been
started or completed.
Measures
Sociodemographic and clinical information was obtained
from informed consent (date of diagnosis, date of birth) and
the questionnaire (marital status, education level, treatment
options, treatment choice, and self-administered co-morbid-
ities). Eligible treatments and the received treatment were ver-
ified through the patient’s medical record; this data was also
used for a separate analysis of treatment choices within this
trial [31]. Individual differences between patients in general
anxiety and depression symptoms were assessed with the
Hospital Anxiety and Depression Scale (HADS) [32].
Main outcome of this study was decisional conflict, which
was measured with the Dutch version of Decisional Conflict
Scale (DCS), incorporating five subscales regarding feeling un-
informed, values clarity, perceived support, decision uncertain-
ty, and the perceived effectiveness of the decision. Scales were
converted to 0 to 100, with higher scores indicating more per-
ceived conflict [33, 34]. Internal consistency of the full scale
was good (Cronbachs alpha, 0.87, subscales 0.58–0.86).
Secondary outcomes included two single items on the patient’s
perceived role during decision-making (Problem-Solving
Decision-Making Scale) and the perceived preparedness to
make the treatment decision (Preparation for Decision-making
Scale, alpha = 0.97) [35, 36]. Pca knowledge was assessed with
an estimation of the perceived knowledge level per treatment
(e.g. BHow well do you think your knowledge about surgery
is?^) and an objective test consisting of fivemultiple-choice test
questions from the Pca Decision Quality Instrument [37].
Additionally, satisfaction with timing and format of the infor-
mation received was measured with the corresponding subscale
of the Satisfaction with Cancer Information Profile (SCIP-B,
alpha = 0.96) [38]. In the DA arm, participants received addi-
tional questions to evaluate the DA (e.g. BWas the online DA
format your preferred format?^ and BWould you preferred if the
DA had provided you with a treatment advice?^).
Statistical analyses
Descriptive statistics are presented as means (+/− SD) for con-
tinuous variables and frequencies and percentages for
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categorical variables. Differences between study arms and be-
tween responders and non-responders were tested using inde-
pendent sample t tests for continuous variables and chi-square
analyses for categorical variables.
Analyses were performed according to the intention-to-
treat principle, assuming that counseling in the DA group
was different from the control group because of the introduc-
tion of the DA, regardless of actual DA usage by participants.
To take the hierarchical structure of the data—due to random-
ization at hospital level—into account and control for hospital
specific effects, linear multilevel regression analyses were
used to test the effect of the intervention (the DA) compared
to the control group. Study arm (DA vs. usual care) was in-
cluded in the model as an independent variable. Dependent
variables consisted of decisional conflict, involvement,
knowledge, and information satisfaction. Participants’
HADS scores served as covariate as anxiety and depression
symptoms are common after receiving a cancer diagnosis and
are known to be related to the evaluation of information pro-
vision [39, 40]. Subgroup analyses were performed on partic-
ipants from which DA log data indicated the DAwas actually
used. Participants were grouped according to their DA format
preference (online versus paper) and HADS score. HADS
scores were initially categorized into normal (0–7), mild
[8–10], moderate [11–14], and severe (≥ 15), according to
previous studies [41]. Because differences between the mild
and moderate group are of little clinical relevance, and to
ensure higher statistical power, the mild and moderate catego-
ries were collapsed into one group.
The study was powered to detect a clinically relevant effect
size of 0.50 between both study arms on decisional conflict. A
conservative intra-class coefficient (ICC) of 0.01 was taken;
therefore, to obtain 80% power and allow for 25% attrition in
the current questionnaire and follow-ups, 238 patients per
study arm were targeted [18]. Eventually, fewer patients than
targeted were recruited for the control group (n = 109). Due to
the conservative sample size calculation, power for making
comparisons between arms was still sufficient (> 0.80), but
low for comparing smaller subgroups (0.65–0.67). Statistical
analyses were conducted using the SPSS 22.0 (Statistical
Package for Social Sciences, Chicago, IL). Tests were two-
sided and considered statistically significant if p < 0.05.
Results
Based on national cancer registry data, the estimated total num-
ber of eligible patients during the trial period was 2000 patients,
of which 484 patients were invited to participate in the trial. A
total of 382 Pca patients signed informed consent (DA= 273 and
control = 109, consent rate 79%), and 336 patients filled out the
post-decision questionnaire (response rate 88%). The mean age
of responders was 65.3 (SD= 5.9), there were no differences in
sociodemographic or clinical characteristics in participants be-
tween both study arms (Table 1). Questionnaire non-responders
were younger than responders (M= 62.9 vs.M = 65.3, p = 0.01),
although the distribution among age groups was comparable
(p= 0.18; Table 2). Furthermore, non-responders were less likely
to have accessed the DA compared to responders (68 vs. 86%,
p = 0.005). The number of patients enrolled per hospital varied
between 1 and 64 (Table 1), response rates from all hospitals
except one were higher than 80% (Table 2).
Between trial arms, no differences were found on involve-
ment or decisional conflict (Table 3). Participants in the DA
arm felt more knowledgeable, but less prepared to make a
decision (Table 3). Overall information satisfaction was lower
in the DA arm, in particular for information usability, the
amount of information, and completeness of the information
(Table 3). The mean objective knowledge (test) scores were
comparable between trial arms (Table 3); however, within the
control arm, knowledge scores were lower for patients eligible
for 3 or 4 treatments (F(2, 84) = 5.84, p = 0.004), while in the
DA arm, test scores were unrelated to the number of eligible
treatments.
A subgroup analysis revealed that 84% of actual DA users
(N = 156) were in favor of the online DA format and 16%
(N = 30) would preferred to have received the DA in print.
Of participants who received but did not access the DA,
56% (N = 15) indicated a DA in print was preferred.
Participants favoring the online DA format were younger
(M = 64.6 vs. M = 67.3, p = 0.02) and more often highly edu-
cated (50% highly educated vs. 27%, p = 0.04). Mean HADS
scores were not statistically significantly different between
both format preference groups, however, medium or severe
HADS scores were more common in participants who would
prefer a printed DA (p = 0.03). DA users in favor of the online
DA format and with HADS scores < 8 reported less decisional
conflict and more information satisfaction compared to other
DA users (Table 4). A treatment advice from the DA was
preferred more often by DA users with severe of high
HADS scores, although differences did not reach statistical
significance (Table 4). No other sociodemographic variables
were associated to differences between DA users. The same
HADS categorization did not yield statistically significant dif-
ferences in the control arm (data not shown).
Discussion
In this pragmatic cluster randomized controlled trial among
patients with localized Pca, adding an online DA to standard
counseling did not lead to different levels of patient involve-
ment or decisional conflict in comparison to standard counsel-
ing. Patients who used the DA did feel more knowledgeable
about Pca treatments but scored equally well as participants
from the control group on a knowledge test. Small negative
Support Care Cancer
effects of the DAwere found on the scales for preparation for
decision-making and information satisfaction, in particular for
DA users with medium or high anxiety and depression symp-
toms or who would preferred the DA to be in print.
With the DA, patients were provided with structured infor-
mation about Pca and possible treatments. Treatment
advantages and disadvantages were presented in a balanced
manner, and VCMs were included to help patients establish a
treatment preference based on personal values [30]. An earlier
investigation into treatment choices within this trial revealed
that with the current DA, the treatment decisions were more
often in line with the patient’s preference instead of the
Table 1 Sociodemographic and
clinical characteristics of
participants
Characteristics Total (n = 336) DA arm (n = 235) Control arm (n = 101) p
Patients
Age at informed consent, mean (SD) 65.3 (5.9) 64.9 (6.0) 66.3 (5.7) .06
≤ 55, n (%) 23 (7%) 16 (7%) 7 (7%) .09
56–65, n (%) 141 (42%) 109 (46%) 32 (32%)
66–75, n (%) 166 (49%) 106 (45%) 60 (59%)
≥ 76, n (%) 6 (2%) 4 (2%) 2 (2%)
Marital status, n (%)
Married/living together 295 (88%) 208 (89%) 87 (87%) .70
Other 41 (12%) 27 (11%) 13 (13%)
Education, n (%)
Low 112 (34%) 76 (33%) 36 (36%) .41
Medium 82 (25%) 54 (23%) 28 (28%)
High 137 (41%) 101 (44%) 36 (36%)
Gleason score, n (%)
6 178 (63%) 134 (61%) 44 (69%) .25
7 106 (37%) 86 (39%) 20 (31%)
PSA level, mean (SD) 7.9 (3.8) 8.3 (3.5) .41
≤ 10.0, n (%) 253 (79%) 180 (79%) 73 (79%) .88
10.1–20.0, n (%) 68 (21%) 49 (21%) 19 (21%)
Number of eligible treatments
2 74 (23%) 49 (21%) 25 (28%) .51
3 157 (49%) 115 (50%) 42 (46%)
4 89 (28%) 65 (29%) 24 (26%)
Anxiety and depression, mean (SD) 7.3 (6.2) 7.3 (6.4) 7.1 (5.5) .76
Normal (0–7), n (%) 192 (62%) 131 (61%) 61 (63%) .77
Mild (8–10), n (%) 46 (15%) 31 (14%) 15 (16%)
Moderate (11–14), n (%) 36 (11%) 24 (11%) 12 (12%)
High (≥ 15), n (%) 38 (12%) 29 (14%) 9 (9%)
DA usage
Yes, n (%) 203 (86%) 203 (86%) n/a
No, n (%) 32 (14%) 32 (14%) n/a
Hospitals1, n (%)
1 11 (5%)
2 1 (1%)
3 46 (19%)
4 28 (12%)
5 13 (6%)
6 17 (7%)
7 64 (27%)
8 35 (15%)
9 20 (8%)
10 6 (6%)
11 18 (18%)
12 9 (9%)
13 9 (9%)
14 23 (23%)
15 8 (8%)
16 20 (20%)
17 8 (8%)
18 0 (0%)
P values report comparisons between the intervention arm and the control arm according to t tests for means and
χ2 tests for frequencies. Numbers may not always add up to the same n due to missing data (e.g. item non-
response), percentages were rounded
1All hospitals were general hospitals, except hospital 14 (academic)
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doctor’s preference [31]. However, this did not translate into
an effect on decisional conflict in the current study, with pre-
vious Pca DA studies also finding mixed results on this out-
come [27] . Possibly, this is because of the nature of the con-
cept of decisional conflict. Despite the wide use of decisional
conflict as an outcome measure in DA evaluations, it has been
debated whether lowering decisional conflict should actually
be the desired outcome of a DA intervention [26, 27, 42, 43].
Careful consideration of all available treatment options, in-
cluding weighing pros and cons against personal preferences,
could evoke conflict and the perceived decision difficulty,
regardless of interventions to support the decision-making
process. If ultimately, the final decision has a better patient-
treatment fit, existence or even increase of decisional conflict
could also be the expense of a thorough decision-making pro-
cess [44, 45]. Follow-up evaluation of our trial participants is
planned to determine if patients are more satisfied with the
selected treatment and experience less regret, after treatment
is completed, compared to patients from the control group.
Next to finding no effect on decisional conflict, the effects
from the DA on the secondary outcomes, preparation for
decision-making and information satisfaction, were small but
opposite from what was expected and overall findings in DA
studies [18, 26]. Although patients were unaware of randomiza-
tion at hospital level and were not informed that the DAwas the
subject of this study, care providers were aware that the purpose
of the study was to compare the DA to usual information rou-
tines. During counseling, the novelty of the DAmight have been
over-emphasized, increasing patients’ expectations and leading
to a more critical evaluation of the DA in the questionnaire. An
indication that some participants might have had other expecta-
tions from the DAwas found in the proportion of patients who
indicated they would like to have received an explicit treatment
advice from the DA, while this was not provided by the DA.
Some evidence for an effect of the DA on knowledge was
found. Firstly, participants with a DA perceived themselves to
be more knowledgeable. Secondly, participants in the DA
group scored equally well on the knowledge test, regardless
of the number of eligible treatments, while in the control
group test scores were lower if the number of eligible treat-
ment options increased. This could indicate that when more
treatments are considered, the DA helps to gain more knowl-
edge about all options resulting in a better informed treatment
decision, while in the control group there might have been
more focus on a single treatment [42].
Not all participants seemed equally suited to receive the DA
in its current online format. Older and lower educated partici-
pants indicated more often that a print DA was preferred over
the current online format. Internet access is common in the
Netherlands, also among elderly, of all people aged up to
75 years, 97% has internet access at home (statline.cbs.nl).
However, with increasing age, actual usage and comfort in
using internet is lower, which could explain some hesitation
among participants to engage in an online tool for making a
high impact treatment decision [46]. Participants with anxiety
and depression symptoms showed more decisional conflict and
less information satisfaction with the DA compared to
participants with similar symptoms from the control
condition. Anxiety and depression is common after a cancer
diagnosis [39]. However, for participants in the control
Table 2 Comparison of questionnaire responders versus non-responders
Characteristics Questionnaire,
responders
(n = 336)
Questionnaire,
non-responders
(n = 46)
p
Patients
Age at informed consent,
mean (SD)
65.3 (5.9) 62.9 (6.1) .01
≤ 55, n (%) 23 (7%) 5 (11%) .18
56–65, n (%) 141 (42%) 25 (54%)
66–75, n (%) 166 (49%) 16 (35%)
≥ 76, n (%) 6 (2%) 0 (0%)
Number of eligible treatments
2 74 (23%) 9 (21%) .32
3 157 (49%) 26 (60%)
4 89 (28%) 8 (19%)
DA usage
Yes, n (%) 203 (86%) 26 (68%) .005
No, n (%) 32 (14%) 12 (32%)
Hospitals1, n (%)
1 11 (55%) 9 (45%) .02
2 1 (100%) 0 (0%)
3 46 (92%) 4 (8%)
4 28 (82%) 6 (18%)
5 13 (81%) 3 (19%)
6 17 (81%) 4 (19%)
7 64 (89%) 8 (11%)
8 35 (92%) 3 (8%)
9 20 (95%) 1 (5%)
10 6 (100%) 0 (0%)
11 18 (90%) 2 (10%)
12 9 (90%) 1 (10%)
13 9 (90%) 1 (10%)
14 23 (96%) 1 (4%)
15 8 (100%) 0 (0%)
16 20 (87%) 3 (13%)
17 8 (100%) 0 (0%)
18 0 (100%) 0 (0%)
P values report comparisons between responders and non-responders,
according to t tests for means and χ2 tests for frequencies. Numbers
may not always add up to the same n due to missing data (e.g. item
non-response), percentages were rounded. Marital status, education level,
Gleason score, PSA level, and HADS scores were not available for non-
responders
1 Rows add up to 100% to represent response rates per hospital
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condition, we did not find a moderating role of anxiety and
depression symptoms on decisional conflict or information
satisfaction. This could indicate that without a DA, care
providers were able to tailor their counseling according to the
estimated level of anxiety and depression, while with the DA,
all information about risks and side effects was presented
equally explicit to all patients. Communicating uncertainty
can lead to lower satisfaction, in particular if patients are more
sensible to this because of anxiety or depression [44]. Further
research is needed to determine if these groups require further
tailored information provision or more guidance in using a DA.
The role of the DA in tailored information should be inves-
tigated in future research. During the current trial, most men
received the DA soon after diagnosis, and were instructed to
use the DA after consultation, regardless of any psychosocial
distress from receiving the Pca diagnosis. Distress could have
hindered uptake of new information from the DA and the
decision-making process [47]. Possibly, some patients benefit
frommore extensive nurse counseling throughout the decision
process and emotions caused by the diagnosis before the DA
is introduced. Detailed analysis (by audio or video) of clinical
consultations could be helpful to investigate to what extent
psychosocial distress plays a role during treatment counseling,
and if the DA is of more added value with a tailored approach
with various levels of nurse guidance [48].
A major strength of this study was the cluster randomized
design to reduce the risk of contamination of standard
counseling with components of the DA. Consequently, care
providers in the DA arm were able to develop a routine in
distributing and explaining the DA. Furthermore, many pa-
tients were recruited in the DA arm and once distributed,
many patients used the DA.
Some limitations need to be mentioned as well. Firstly,
recruitment of participants in the control arm was slower and
resulted in less participants than aimed for. Although patient
characteristics were very similar in both arms, we cannot ex-
clude a potential selection bias in the control arm which may
have led to recruiting only patients who were more likely to
consent. Secondly, as mentioned before, care providers were
aware of randomization and the true focus of this study. In the
control arm, this could have led to modifications of existing
information or counseling routines due to the increased
Table 3 Effects of the DA
Outcome DA group, N = 235
Mean (SD)
Control group, N = 101
Mean (SD)
β p
Involvement
Weighing treatment pros and cons 3.3 (0.8) 3.2 (0.8) 0.25 0.12
Treatment decision 3.6 (0.9) 3.5 (0.8) 0.07 0.50
Preparation for decision-making 3.6 (0.9) 4.2 (0.6) − 0.55 < 0.001
Decisional conflict
Full scale 23.5 (13.4) 24.1 (13.0) − 1.30 0.39
Informed subscale 16.8 (16.1) 17.7 (17.1) − 1.03 0.60
Values clarity subscale 30.0 (17.8) 31.8 (17.0) − 2.55 0.30
Support subscale 22.4 (16.7) 21.1 (16.0) 0.07 0.97
Uncertainty subscale 33.9 (23.5) 33.5 (21.2) − 0.75 0.81
Effective decision subscale 16.8 (14.3) 18.4 (15.9) − 1.99 0.26
Knowledge
Objective knowledge 7.5 (2.1) 7.2 (2.0) 0.32 0.30
Subjective knowledge 7.0 (1.4) 6.6 (1.5) 0.43 0.01
Satisfaction with information
Full scale 3.8 (0.8) 4.1 (0.6) − 0.25 0.04
Information usability for patient 3.8 (0.9) 4.1 (0.7) − 0.35 0.01
Information usability for spouse 3.7 (1.0) 4.1 (0.7) − 0.33 0.02
Amount of written information 3.8 (0.9) 4.1 (0.8) − 0.37 0.02
Amount of oral information 3.7 (0.9) 4.1 (0.8) − 0.36 0.02
Information completeness 3.7 (0.9) 4.1 (0.7) − 0.40 0.01
Information comprehensiveness 3.9 (0.9) 4.1 (0.8) − 0.14 0.31
Information accessibility 3.9 (0.9) 4.1 (0.7) − 0.14 0.30
Moment of receipt 4.0 (0.9) 4.1 (0.7) − 0.10 0.39
Delivery method 4.1 (0.9) 4.1 (0.8) − 0.06 0.58
Means and standard deviations (SD) are presented as observed in the dataset. Beta’s represent the effect of the DA
compared to the control group as obtained from linear multilevel regression analyses, controlling for HADS score
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attention for SDM from this study, or in the DA group, to the
creating of too high expectations as care providers could have
(over-)emphasized the novelty of the DA. Thirdly, although
the DA achieved a high usage rate, non-users were more likely
to also not respond to the questionnaire. The evaluation of
patient who chose not to use the DA are therefore underrep-
resented in the current sample. A qualitative study could pro-
vide more insights in their motives to not use the DA.
Table 4 Subgroup analysis of actual DA users in the intervention arm (N = 186, missing N = 171)
Outcome Format preference Anxiety and depression symptoms
Online N = 156 Paper N = 30 Normal (0–7)
N = 114
Medium (8–14)
N = 48
Severe (≥ 15)
N = 24
Anxiety and depression symptoms, mean (SD) 6.9 (6.2) 9.4 (6.9) 3.4 (2.3) 10.3 (1.8) 20.4 (3.9)
Normal (0–7), N (%) 102 (65%) 12 (40%)* 114 (100%) – –
Medium (8–14) 35 (22%) 13 (43%) – 48 (100%) –
Severe (≥ 15) 19 (12%) 5 (17%) – – 24 (100%)
Weighing treatment pros and cons, mean (SD) 3.5 (0.8) 3.0 (0.5) ** 3.4 (0.8) 3.4 (0.8) 3.3 (0.7)
Doctor-driven, N (%) 14 (9%) 4 (13%) ** 9 (8%) 4 (8%) 5 (22%)
Shared, N (%) 74 (48%) 22 (75%) 59 (52%) 28 (60%) 8 (35%)
Patient-driven, N (%) 67 (43%) 4 (13%) 46 (40%) 15 (32%) 10 (43%)
Making the treatment decision, mean (SD) 3.7 (0.9) 3.3 (0.8) * 3.6 (0.8) 3.6 (0.8) 3.8 (0.9)
Doctor-driven, N (%) 9 (6%) 2 (6%) * 7 (6%) 3 (6%) 1 (4%)
Shared, N (%) 64 (41%) 21 (68%) 54 (48%) 20 (42%) 10 (42%)
Patient-driven, N (%) 83 (53%) 8 (26%) 53 (46%) 25 (52%) 13 (54%)
Preparation for decision-making, mean (SD) 3.6 (1.0) 3.5 (0.8) 3.6 (1.0) 3.7 (0.8) 3.4 (0.9)
Decisional conflict, mean (SD)
Full scale 22.1 (12.4) 28.8 (13.4) ** 21.9 (11.6) 23.7 (11.9) 28.6 (18.1)
Informed subscale 15.1(15.2) 21.5 (19.0) * 16.5 (17.8) 14.6 (12.6) 17.0 (13.6)
Values clarity subscale 28.1 (17.9) 38.4 (13.4) ** 28.6 (18.3) 30.7 (14.2) 33.7 (20.3)
Support subscale 20.2 (15.1) 26.3 (17.0) * 20.2 (13.7) 20.1 (14.8) 29.2 (22.1) *
Uncertainty subscale 33.1 (22.2) 37.6 (25.4) 31.3 (20.8) 35.6 (21.7) 44.1 (29.9) *
Effective decision subscale 15.9 (13.2) 22.2 (17.5) * 15.2 (12.9) 19.0 (13.2) 21.6 (19.5) *
Knowledge, mean (SD)
Objective knowledge 7.7 (2.0) 7.4 (1.9) 7.6 (2.0) 7.8 (2.2) 7.8 (1.7)
Subjective knowledge 7.2 (1.2) 6.0 (1.7) *** 7.1 (1.4) 7.2 (1.0) 6.4 (1.4)
Satisfaction with information, mean (SD)
Full scale 3.9 (0.8) 3.5 (1.0) * 3.9 (0.7) 3.8 (0.9) 3.5 (0.9) *
Information usability for patient 3.8 (0.9) 3.4 (1.1) * 3.8 (0.8) 3.7 (1.0) 3.3 (1.1) *
Information usability for spouse 3.8 (0.9) 3.4 (1.1) * 3.8 (0.9) 3.7 (1.0) 3.3 (1.1) *
Amount of written information 3.8 (0.8) 3.5 (1.1) * 3.8 (0.8) 3.7 (1.0) 3.5 (0.9)
Amount of oral information 3.8 (0.9) 3.5 (1.0) 3.8 (0.8) 3.7 (1.0) 3.4 (1.1)
Information completeness 3.7 (0.9) 3.5 (1.0) 3.8 (0.9) 3.7 (1.0) 3.4 (1.0)
Information comprehensiveness 4.0 (0.8) 3.6 (1.0) * 4.0 (0.8) 3.9 (1.0) 3.6 (0.9) *
Information accessibility 4.0 (0.9) 3.6 (1.1) * 4.1 (0.8) 3.8 (1.0) 3.6 (1.0) *
Moment of receipt 4.1 (0.9) 3.7 (1.0) * 4.1 (0.9) 4.0 (1.0) 3.7 (0.9) *
Delivery method 4.1 (0.9) 3.7 (0.9) ** 4.2 (0.9) 4.0 (0.9) 3.7 (0.9) *
Preferred treatment advise from DA, N (%) 49 (31%) 11 (31%) 28 (26%) 17 (37%) 10 (44%)
Means and standard deviations (SD) are presented as observed in the dataset. P values report comparisons between subgroups according to the
appropriate test (i.e., t tests or Anova with Bonferroni post-hoc tests for means and χ2 tests for frequencies)
*p < 0.05
**p < 0.01
***p < 0.001
1Missing due to item non-response or missing DA user data
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This study measured DA effects immediately following
treatment decision-making. Previous research showed that ef-
fects fromVCMs included in DAs could also emerge at a later
point than at treatment decision-making [49]. Post-treatment
follow-ups in the current sample on treatment satisfaction and
decisional regret are needed to determine if this is also the case
for this DA [18].
In conclusion, this study did not find evidence of beneficial
effects from the DA on patient-reported decision process pa-
rameters. Importantly, patients who do not favor the online
DA format or present with anxiety and depression symptoms
could require more guidance and support during DA use and
treatment counseling. The effect of the DA on treatment sat-
isfaction and decisional regret once treatment is completed,
needs to be investigated in a follow-up study.
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